Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1572-0241.2007.01326.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraoperative indocyanine green with ultrasound-guided localization as prodigious adjuncts explicating negative margin in functional insulinoma: A case report.
Int J Surg Case Rep
January 2025
Department of Gastrointestinal and General Surgery, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal.
Introduction And Importance: Insulinomas are rare pancreatic neuroendocrine neoplasms with an incidence of one to four cases per million annually and a 5 % to 10 % association with hereditary multiple endocrine neoplasia type-1. While most insulinomas are benign and well-encapsulated, approximately 6 % may have malignant potential. Intraoperative localization remains a vital component of treatment, often facilitated by modern imaging techniques like intraoperative ultrasound and fluorescence modalities.
View Article and Find Full Text PDFComprehensive approach to esophageal variceal bleeding: From prevention to treatment.
World J Gastroenterol
November 2024
Department of Medicine and Surgery, University of Enna 'Kore', Enna 94100, Sicilia, Italy.
Esophageal variceal bleeding is a severe complication often associated with portal hypertension, commonly due to liver cirrhosis. Prevention and treatment of this condition are critical for patient outcomes. Preventive strategies focus on reducing portal hypertension to prevent varices from developing or enlarging.
View Article and Find Full Text PDFSUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.
Ther Adv Med Oncol
November 2024
Hôpital Edouard Herriot, Lyon, France.
Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.
Patients And Methods: In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Insulinoma with suspected mutant somatostatin receptor expression according to histological examination.
Clin Case Rep
November 2024
Department of Diabetes, Metabolism, and Endocrinology International University of Health and Welfare, Narita Hospital Chiba Japan.
Article Synopsis
- * A specific case involving a 69-year-old Japanese woman showed that preoperative tests indicated low expression of somatostatin receptors (SSTR2 and SSTR5), but after surgery, the tumor exhibited strong SSTR expression.
- * This case highlights the unusual situation where the insulinoma had mutated forms of SSTRs, leading to contradictory findings between preoperative assessments and postoperative pathology results.
Octreotide Causing Hyperkalemia: A Case Report and Review of the Literature.
Cureus
August 2024
Nephrology, State University of New York (SUNY) Downstate Health Sciences University, New York City, USA.
Article Synopsis
- Octreotide is a synthetic version of somatostatin that helps inhibit hormones like growth hormone and insulin, and is used in conditions such as acromegaly and carcinoid tumors.
- A 44-year-old man with type 2 diabetes and advanced kidney disease experienced severe hypoglycemia from sulfonylureas and was treated with octreotide, which unfortunately caused hyperkalemia as a side effect.
- This case underscores the risks of using octreotide in patients with renal impairment, highlighting the need for careful monitoring of potassium levels to prevent serious complications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!